...
Bloomberg.com:
U.S.
Updated: New York:
Nov 04 01:00London:
Nov 04 06:00Tokyo:
Nov 04 15:00
US AUBZFPGRHKIMJPLNSMIND
:
Regions
Top Worldwide
Regions
Asia
Australia & New Zealand
Canada
Europe
Germany
Japan
Latin America
U.K.
U.S.
Markets
Economy/Politics
Commentary
Sports
Culture
RESOURCES:
Bloomberg TV
Bloomberg Radio
Markets
U.S.
E-Mail This Story
Printer-Friendly Format
Sovereign's Santander $2.4 Billion Deal an `Outrage,' Franklin Mutual Says
U.S.
Probably Added 120,000 Jobs in October, Reflecting Hurricane Losses
Refco Auction Suffers Setback as Tradelink Pulls Out on Liability Concern
Merck's Vioxx Victory May Not Help Future Cases, Analysts Say Nov.
4 (Bloomberg) - Merck & Co.
can't savor yesterday's
victory in the second trial over its Vioxx painkiller for long,
say analysts and lawyers tracking the 6,400 other lawsuits the
company faces for injuries or deaths linked to the drug.
Merck, the No.
3 U.S.
drugmaker, faces its next trial on
Nov.
28 in Houston, where a widow of a Vioxx user claims her
husband died after one month on the drug.
Analysts say Merck
faces billions of dollars in potential liability from such cases
following its New Jersey victory.
A jury in Atlantic City ruled yesterday that Merck wasn't
liable to an Idaho postal worker, Frederick Humeston, who blamed
his 2001 heart attack on the drug.
The victory followed an
August verdict by Texas jury that told Merck to pay the widow of
a Vioxx user $253 mill...
Read more...